Cryoport: Picks And Shovels For The Gene Therapy Boom

Cryoport, Inc. (CYRX) is the leading provider of temperature-controlled supply chain solutions for the rapidly growing cell and gene therapy industry. CYRX supports 745 clinical trials and 19 commercial therapies, with commercial segment revenue up 36% YoY, reflecting accelerating industry adoption. Despite strong growth and a dominant market position, CYRX trades at depressed valuations, offering a deep value opportunity for patient investors.

Seeking Alpha • Dec 2, 2025

Cryoport Systems Wins 2025 BioTech Breakthrough Award For “BioServices Innovation of the Year”

Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World

GlobeNewsWire • Nov 6, 2025

Cryoport Reports Strong Q3 Results, Raises FY25 Outlook

Cryoport Inc (NASDAQ:CYRX) reported third-quarter financial results after the market close on Tuesday. Here's a rundown of the temperature-controlled supply chain solutions company's report.

Benzinga • Nov 4, 2025

Cryoport, Inc. (CYRX) Q3 2025 Earnings Call Transcript

Cryoport, Inc. ( CYRX ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief Administrative Officer Mark W. Sawicki - Senior VP & Chief Scientific Officer Thomas Heinzen - Vice President of Corporate Development & Investor Relations Conference Call Participants Todd Fromer - Kanan, Corbin, Schupak & Aronow, Inc. Kyle Crews - UBS Investment Bank, Research Division David Saxon - Needham & Company, LLC, Research Division Puneet Souda - Leerink Partners LLC, Research Division Matthew Stanton - Jefferies LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division David Larsen - BTIG, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Presentation Operator " Jerrell Shelton Chairman, President & CEO " Robert Stefanovich Senior VP, CFO, Treasurer & Chief Administrative Officer " Mark W.

Seeking Alpha • Nov 5, 2025

Cryoport Reports Third Quarter 2025 Financial Results

Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-year Company updates full year 2025 revenue guidance of $170 to $174 million NASHVILLE, Tenn. , Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025.

PRNewsWire • Nov 4, 2025

CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.02 per share a year ago.

Zacks Investment Research • Nov 4, 2025

Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain

First Global Supply Chain Solutions Company to Achieve ISO 21973 Certification, Ensuring Highest Transport Safety, Traceability, and Integrity Standards for Cell and Gene Therapies NASHVILLE, Tenn. , Oct. 30, 2025 /PRNewswire/ -- Cryoport, Inc.  (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems, a Cryoport company, has successfully achieved certification under ISO 21973:2020, the international standard for transportation of human cells for therapeutic use published by the International Organization for Standardization (ISO).

PRNewsWire • Oct 30, 2025

Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025

NASHVILLE, Tenn. , Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close.

PRNewsWire • Oct 21, 2025

CryoPort (CYRX) Moves 7.0% Higher: Will This Strength Last?

CryoPort (CYRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Oct 17, 2025

MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars

Connected, Intelligent Condition Monitoring Assets that Safeguard Vital Life Science Materials Mark MVE's First Step in its Real-Time Integrated Systems Evolution NASHVILLE, Tenn. , Oct. 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences, today announced the unveiling of  MVE Biological Solutions ' ("MVE") integrated Condition Monitoring Solutions for its MVE SC 4/2 V and 4/3 V series dewars, both powered by Tec4Med, another Cryoport company.

PRNewsWire • Oct 7, 2025